Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Covidien PLC's Subsidiary Prices $1.250 Billion Senior Notes Offering
Covidien PLC announced that ts wholly-owned subsidiary, Covidien International Finance S.A. (CIFSA), priced an underwritten offering of $600 million aggregate principal amount of 1.350% senior notes due 2015 and $650 million aggregate principal amount of 3.200% senior notes due 2022. The offering is expected to close on May 30, 2012. The notes will be CIFSA’s senior unsecured obligations and will rank equally in right of payment with all of its existing and future senior debt, and senior to any subordinated indebtedness that CIFSA may incur. These notes are fully and unconditionally guaranteed on a senior unsecured basis by Covidien plc and its subsidiary, Covidien Ltd. CIFSA intends to use the net proceeds of this offering to fund the redemption of all of its outstanding 5.450% senior notes due October 2012 and for general corporate purposes.
Latest Developments for Covidien PLC
- Covidien PLC Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue And Significantly Reduces Disease Progression
- Covidien PLC Receives FDA 510(k) Clearance For Nellcor Pulse Oximetry Motion Claims
- Covidien PLC Lowers FY 2013 Revenue Guidance
- Covidien PLC Expands Share Repurchase Program and Declares Quarterly Cash Dividend
Latest Key Developments in Advanced
- Share this
- Link this
- Digg this


Follow Reuters